Pheochromocytoma Market Driver, Trends and Forecast Research Report to 2025

Posted by vinit sawant on February 9th, 2021

The global pheochromocytoma market is growing owing to the increasing investment by major companies to develop specific treatment options, high prevalence of pheochromocytoma, and an increasing number of clinical trials for drugs for pheochromocytoma. Furthermore, the rapidly changing lifestyle, rising healthcare expenditure, and increasing incidence rate of rare tumors are also expected to fuel the market growth.

According to MRFR analysis, Pheochromocytoma Market is expected to register a CAGR of 3.84% during the forecast period of 2019 to 2025. The global market was valued at USD 2,814.75 Million in 2018.

Several market players currently dominate the global pheochromocytoma market. The key players are involved in product launches and acquisitions to strengthen their market positions.

Segmentation

The Global Pheochromocytoma Market has been segmented based on treatment type and end-user.

The global pheochromocytoma market has been segmented, on the basis of treatment type, into alpha-blockers, beta-blockers, surgery, radionuclide treatment, and others. The surgery segment is expected to hold the largest market share as it is the most preferred treatment option for pheochromocytoma. The radionuclide treatment is expected to grow at the fastest CAGR owing to an increasing number of applications of radiopharmaceuticals in the treatment of various diseases

The market based on end-user has been segmented into hospitals & clinics, research & academic institutes, and others. Hospitals and clinics are the first point of treatment for any disease; hence it is expected to hold the largest market share. Research & academic institutes are expected to grow at the fastest CAGR owing to increasing research & development activities for better treatment options for pheochromocytoma.